← Eichor
Study identifier: NCT05035147 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

Condition: Pancreatic Cancer  ·  Sponsor: Tianjin Medical University Cancer Institute and Hospital

PhasePhase 4
Planned participants934
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to further observe and evaluate whether the three-week administration of albumin-bound paclitaxel combined with gemcitabine is equivalent to the four-week administration in the treatment of inoperable locally advanced or metastatic pancreatic cancer

This description comes directly from the study's public registry record.

Talk to the study team

Liu rui, professor  ·  13602139003  ·  Liurui9003@163.com

Ji zhi, professor  ·  18526643284  ·  jizhikey@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Rui LiuTianjin, Tianjin Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05035147